Form 4: Vir Biotechnology Director Acquires Shares and Options in Recent Transaction

Director George A. Scangos reports acquisition of Vir Biotechnology shares and options, along with adjustments to beneficial ownership.

Summary

• On May 30, 2024, George A. Scangos, a director of Vir Biotechnology, Inc., acquired 8,000 shares of common stock at $0 and 16,000 stock options with an exercise price of $10.39.
• The options are exercisable from May 30, 2025, to May 29, 2034.
• Following the transaction, Scangos directly owns 120,989 shares of common stock.
• Scangos also indirectly owns 1,750,000 shares through the George A Scangos 2023 Annuity Trust, 1,750,000 shares through the Leslie Wilson 2023 Annuity Trust, 33,629 shares through the Scangos-Wilson Family Trust, and 179,930 shares through the Scangos 2018 Grandchildren's Trust.
• He also directly owns 16,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing transactions by a company insider. The acquisition of shares and options could be interpreted as a positive sign, but it's not definitively bullish.

Positives

• The acquisition of shares and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to insider trading activities, which are common in publicly traded companies. It provides transparency to investors regarding the actions of company insiders.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.
• The acquisition of shares by a director may signal confidence in the company's prospects, potentially influencing investor sentiment.

Key Dates